Delivery of antigens used for vaccination: Recent advances and challenges

Therapeutic Delivery

Volumn 2, Issue 10, 2011, Pages 1351-1368

  Scherließ, Regina ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM SALT; ANTIGEN; BCG VACCINE; CHOLERA TOXIN B SUBUNIT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; FREUND ADJUVANT; GOLD NANOPARTICLE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; QS 21; ROTAVIRUS VACCINE; STIMUVAX; TOXOID; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

BREAST CANCER; DEVELOPING COUNTRY; DEVICE; DRUG DELIVERY SYSTEM; DRUG STABILITY; HUMAN; LUNG CANCER; LUNG TUBERCULOSIS; MUCOSAL VACCINATION; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THERMOSTABILITY; TRANSDERMAL VACCINATION; VACCINATION;

EID: 80054121164     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.80     Document Type: Review

References (151)

1. Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. (2008)
2. Mustafa AS. Vaccine potential of Mycobacterium tuberculosis-specific genomic regions: in vitro studies in humans. Exp. Rev. Vaccines 8(10), 1309-1312 (2009)
3. Melnick JL. Current status of poliovirus infections. Clin. Microbiology Rev. 9(3), 293-400 (1996)
4. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 5(5), 428-434 (2010)
5. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 25, 323-338 (1997) (Pubitemid 27453255)
6. Bätzing-Feigenbaum J, Pruckner U, Beyer A et al. Spotlight on measles 2010: preliminary report of an ongoing measles outbreak in a subpopulation with low vaccination coverage in Berlin, Germany. January-March 2010. Eurosurveillance 15(13), 19527 (2010)
7. Deer B. How the case against the MMR vaccine was fixed. BMJ 342, c5347 (2011)
8. Global Immunization Data. Report edited WHO and Unicef, Geneva, Switzerland. 1-4 (2010)
9. GIVS: Global Immunization Vision and Strategy. Report edited by WHO Department of Immunization, Vaccines and Biologicals and UNICEF Programme Division. Health Section, Geneva, 1-84 (2005)
10. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 455, 613-619 (2008)
11. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus Type-1 by vaccination. Cell Press Immunity 33, 542-554 (2010)
12. Sullivan T, Taraporewala I, Zielinski W. Innovations in intranasal vaccine delivery technology. BioPharm. Int. 1-5 (2009)
13. Geisbert TW, Geisbert JB, Leung A et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J. Virology 83(14), 7296-7304 (2009)
14. Lell B, Agnandji S, von Glasenapp I et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4(10), e7611 (2009)
15. Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. EJPB 76, 1-9 (2010)
16. Hwang S-A, Kruzel ML, Actor JK. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int. Immunopharmacol. 5, 591-599 (2005) (Pubitemid 40430765)
17. Desprès P, Combredet C, Frenkiel M-P, Lorin C, Brahic M, Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J. Infect. Dis. 191, 207-214 (2005) (Pubitemid 40096378)
18. Brandler S, Ruffie C, Najburg V et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28, 6730-6739 (2010)
19. Berthoud TK, Hamill M, Lillie PJ et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 1, 1-7 (2011)
20. Perez SA, von Hofe E, Kallinteris NL et al. A new era in anticancer peptide vaccines. Cancer 116(9), 2071-2080 (2010)
21. Bade S, Frey A. Vaccines against transmissibe spongiform encephalopathies-an urgent need? Human vaccines 4(1), 79-81 (2008) (Pubitemid 351785266)
22. Bade S, Baier M, Boetel T, Frey A. Intranasal immunization of Balb/c mice against prion protein attanuates orally acquired transmissible spongiform encephalopathy. Vaccine 24, 1242-1253 (2006) (Pubitemid 43222031)
23. Mittal SK, HogenEsch H, Park K. Vaccines and other immunological products. In: Encyclopedia of Pharmaceutical Technology, Swabrick J (Ed.) Informa Healthcare USA, Inc., 3908-3927 (2007)
24. Muzzulini T. Immunmodulation of the Th cell differentiation using DNA immunization. Thesis at FU Berlin. FB Biologie, Chemie. Pharmazie 1-106 (2004)
25. Ribeiro CMS, Schijns VEJC. Immunology of vaccine adjuvants. In: Vaccine Adjuvants. Davies G (Ed.) Springer Science+Business Media, LCC, NY, USA 1-14 (2010)
26. Cohen J. The RTS,S malaria vaccine candidate: from concept to pivotal phase 3 testing. Presented at: Vaccine and ISV Annual Conference (2010)
27. Mann JF, Acevedo R, del Campo J, Pérez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Exp. Rev. Vaccines 8(1), 103-112 (2009).
28. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998) (Pubitemid 28155090)
29. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nature Med. Suppl. 11(4), S45-S53 (2005) (Pubitemid 40562303)
30. Kraehenbuhl J-P, Neutra MR. Epithelial M cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16, 301-332 (2000) (Pubitemid 32037509)
31. Hathaway LJ, Kraehenbuhl J-P. The role of M cells in mucosal immunity. CMLS 57, 323-332 (2000) (Pubitemid 30311418)
32. Kiyono H, Fukuyama S. NALT- versus Peyeŕs-patch-mediated mucosal immunity. Nature Rev. Immunol. 4, 699-710 (2004) (Pubitemid 39223076)
33. Davies SS. Nasal vaccines. Adv. Drug Deliv. Rev. 51, 21-42 (2001)
34. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nature Rev. Immunol. 6, 148-158 (2006) (Pubitemid 43361590)
35. Vyas SP, Gupta PN. Implication of nanoparticles/microparticles in mucosal vaccine delivery. Exp. Rev. Vaccines 6(3), 401-418 (2007) (Pubitemid 46911603)
36. Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol. DOI: 10.1016/j. coi.2011.03.009 (2011) (Epub ahead of print)
37. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24(21), 4651-4656 (2006) (Pubitemid 43776781)
38. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 58, 68-89 (2006)
39. Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: Do all ways lead to Rome? J. Control. Release 148, 266-282 (2010)
40. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nature Biotechnol. 28, 573-579 (2010)
41. Gordon SB, French N. Should we develop an inhaled anti-pneumococcal vaccine for adults? Curr. Med. Chem. Anti-infective Agents 4, 75-79 (2005)
42. Riddell A, Buttery J. Vaccines against meningococcal disease: current and future technologies. Exp. Opin. Biol. Ther. 1(3), 385-399 (2001) (Pubitemid 33768657)
43. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin. Infect. Dis. 50 (Suppl. 2), S45-S53 (2010)
44. Nochi T, Tagaki H, Yuki Y et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. PNAS 104(26), 10986-10991 (2007) (Pubitemid 47175213)
45. Jabbal-Gill I, Fisher AN, Rappuolit R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 16(20), 2039-2046 (1998) (Pubitemid 28473954)
46. McNeela EA, O'Connor D, Jabbal-Gill I et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19, 1188-1198 (2001) (Pubitemid 32008285)
47. Singh M, ÓHagan D. Recent advances in vaccine adjuvants. Pharm. Res. 19(6), 715-728 (2002) (Pubitemid 34686729)
48. Holmgren J, Lebens M. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier. Dev. Biol. Stand. 82, 215-227 (1994)
49. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Cell Press Immunity 33, 530-541 (2010)
50. Moriel DG, Scarselli M, Serino L, Mora M, Rappuoli R, Masignani V. Genome-based vaccine development: a short cut for the future. Human Vaccines 4(3), 184-188 (2008)
51. Robinson HL. DNA vaccines: basic mechanism and immune responses. Int. J. Mol. Med. 4(5), 549-604 (1999)
52. Bröker M. Adjuvanzien für Impfstoffe. MMP 25(11), 373-378 (2002)
53. Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Exp. Rev. Vaccines 6(5), 723-739 (2007) (Pubitemid 47607848)
54. Ott G. The adjuvant MF59: the 1998 perspective, clinical performance and mechanism of action. Res. Immunol. 149, 25-27 (1998)
55. Gratton SEA, Ropp PA, Pohlhaus PD et al. The effect of particle design on cellular internalization pathways. Proc. Nat. Acad. Sci. 105(33), 11613-11618 (2008)
56. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004) (Pubitemid 39142021)
57. Chadwick S, Kriegel C, Amiji MM. Delivery strategies to enhance mucosal vaccination. Exp. Opin. Biol. Ther. 9(4), 427-440 (2009)
58. Malyala P, Singh M. Micro/nanoparticle adjuvants: preparation and formulation with antigens. In: Vaccine Adjuvants. Davies G (Ed.) Springer Science and Business Media, LCC, NY, USA, 91-101 (2010)
59. Sharma S, Mukkur TK, Benson HA, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 98(3), 812-843 (2009)
60. Wiley JA, Richert LE, Swain SD et al. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS ONE 4(9), e7142 (2009)
61. Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J. Drug Target. 16(1), 1-17 (2008)
62. Borges O, Cordeiro-da-Silva A, Tavares J et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm. 69(2), 405-416 (2008)
63. Lingnau K, Riedl K, von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Exp. Rev. Vaccines 6(5), 741-746 (2007). (Pubitemid 47607849)
64. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21, S2/89-S82/95 (2003)
65. Legrand D, Elass E, Pierce A, Mazurier J. Lactoferrin and host defence: an overview of its immuno-modulating and anti-inflammatory properties. BioMetals 17, 225-229 (2004) (Pubitemid 38987141)
66. Actor JK, Hwang S-A, Kruzel ML. Lactoferrin as natural immune modulator. Curr. Pharm. Des. 15(17), 1956-1973 (2009)
67. Kanwar JR, Palmano KP, Sun X et al. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Iron-saturated lactoferrin for cancer. Immunol. Cell. Biol. 86, 277-288 (2008) (Pubitemid 351430811)
68. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm. 364, 272-280 (2008)
69. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int. J. Pharm. 217(1-2), 183-191 (2001) (Pubitemid 32268644)
70. Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration. J. Control. Release 121, 168-175 (2007) (Pubitemid 47212538)
71. Aspden TJ, Masen JTD, Jones NS, Lowe J, Skaugrud Ö, Illum L. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J. Pharm. Sci. 86(4), 509-513 (1997) (Pubitemid 27154770)
72. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116, 1-27 (2006) (Pubitemid 44792295)
73. Tafaghodi M, Tabassi SAS, Jaafaria M-R, Zakavid SR, Momen-Nejad M. Evaluation of the clearance characteristics of various microspheres in the human nose by g-scintigraphy. Int. J Pharm. 280(1-2), 125-135 (2004) (Pubitemid 38950910)
74. Krause A, Worgall S. Delivery of antigens by viral vectors for vaccination. Therapeutic Delivery 2(1), 51-70 (2011)
75. Tangy F, Naim HY. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 18(2), 317-326 (2005) (Pubitemid 41106010)
76. Guerbois M, Moris A, Combredet C et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160?V1V2 is strongly immunogenic. Virology 388, 191-203 (2009)
77. Lorin C, Mollet L, Delebecque F et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade b envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virology 78(1), 146-157 (2004) (Pubitemid 37549727)
78. Duc LH, Cutting SM. Bacterial spores as heat stable vaccine vehicles. Exp. Opin. Biol. Ther. 3(8), 1263-1270 (2003) (Pubitemid 38004697)
79. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines 4(1), 5-8 (2008)
80. Vujanic A, Wee JLK, Snibson KJ et al. Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIXTM adjuvanted recombinant antigens. Vaccine DOI: 10.1016/j. vaccine.2010.01.018 (2010) (Epub ahead of print)
81. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 24(1), 45-56 (2006) (Pubitemid 41722204)
82. Tiwari S, Goyal AT, Khatri K, Mishra N, Vyas SP. Gel core liposomes: an advanced carrier for improved vaccine delivery. J. Microencapsulation 26(1), 75-82 (2009)
83. Lemoine D, Deschuyteneer M, Hogge F, Préat V. Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed. 10(8), 805-825 (1999) (Pubitemid 29408386)
84. Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24(19), 4201-4211 (2006)
85. Ho J, Huang Y, Danquah MK, Wang H, Forde GM. Synthesis of biodegradable polymer-mesoporous silica composite microspheres for DNA prime-protein boost vaccination. European J. Pharm. Sci. 39, 412-420 (2010)
86. Tahara K, Yamamoto H, Hirashima N, Kawashima Y. Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. EJPB 74, 421-426 (2010)
87. Singh J, Pandit S, Bramwell VW, Alpar HO. Diphtheria toxoid loaded poly-(E-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96-105 (2006) (Pubitemid 43163469)
88. Moebus K, Siepmann J, Bodmeier R. Alginate-poloxamer microparticles for controlled drug delivery to mucosal tissue. Eur. J. Pharm. Biopharm. 72, 42-53 (2009)
89. Sivadas N, O'Rourke D, Tobin A et al. A comparative study of a range of polymeric microspheres as potential carriers for the inhalation of proteins. Int. J. Pharm. 358, (2008)
90. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21, 1400-1408 (2003) (Pubitemid 36263181)
91. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. 96(3), 473-483 (2007) (Pubitemid 46466073)
92. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81-96 (2001) (Pubitemid 32763074)
93. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411-430 (2005) (Pubitemid 39550968)
94. Prego C, Paolicelli P, Diaz B et al. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine DOI: 10.1016/j.vaccine.2010.01.011 (2010) (Epub ahead of print)
95. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Deliv. Rev. 62, 59-82 (2010)
96. Grenha A, Remunan-Lopez C, Carvalho ELS, Seijo B. Microspheres containing lipid/ chitosan nanoparticles complexes for pulmonary delivery of therapeutic proteins. Eur. J. Pharm. Biopharm. 69, 83-93 (2008)
97. Nochi T, Yuki Y, Takahashi H et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nature Mater. 9, 572-578 (2010).
98. Debin A, Kravtzoff R, Santiago JV et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20(21-22), 2752-2763 (2002) (Pubitemid 34601001)
99. Kojima N, Biao L, Nakayama T, Ishii M, Ikehara Y, Tsujimura K. Oligomannose-coated liposomes as a therapeutic antigen-delivery and an adjuvant vehicle for induction of in vivo tumor immunity. J. Control. Release 129, 26-32 (2008)
100. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J. Pharm. Sci. 92(2), 218-231 (2003) (Pubitemid 36169294)
101. de Swart RL, LiCalsi C, Quirk AV et al. Measles vaccination of macaques by dry powder inhalation. Vaccine 25, 1183-1190 (2007) (Pubitemid 46027344)
102. Nelson C. Effects of Freezing on Vaccine Potency. PATH. 1-4 (2003)
103. Lloyd J. Technologies for Vaccine Delivery in the 21st Century. WHO. 1-25 (2000)
104. Nelson C, Widjaya A, Wittet S. Using Uniject to Increase the Safety and Effectiveness of Hepatitis B Immunzation. PATH Occasional Paper. 6, 1-8 (2002)
105. Geeraedts F, Saluja V, ter Veer W et al. Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures. AAPS 12(2), 215-222 (2010)
106. Arakawa T, Prestrelski SJ, Kenney WC, Carpenter JF. Factors affecting short-term and long-term stabilities of proteins. Adv. Drug Deliv. Rev. 10, 1-28 (1993) (Pubitemid 23158691)
107. Amorij J-P, Huckriede A, Wilschut J, Frijlink HW, Hinrichs WLJ. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 25(6), (2008)
108. Amorij J-P, Meulenaar J, Hinrichs WLJ et al. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine 25, 6447-6457 (2007) (Pubitemid 47198923)
109. Leukocare. Stabilizing composition for immobilized biomolecules. European Patent Application (EP 2236520 A1), 1-36 (2010)
110. Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. SciTranslMed 2(19), (2010)
111. Dubin CH. Prefilled syringes gain favor with pharma, caregivers and patients. Drug Del. Technol. 10(5), 38-41 (2010)
112. Ziegler AS, Schluecker E, Reichel-Lesnianski P, Alt N, Lee G. Inactivation effects on proteins in a needle-free vaccine injector. Eng. Life Sci. 6(4), 384-393 (2006) (Pubitemid 44430431)
113. TM Gene Gun. Plant Mol. Biol. Rep. 18, 287a-2871 (2000)
114. Stoecklinger A, Eticha TD, Mesdaghi M et al. Langerin+ dermal dendritic cells are critical for CD8+ T cell activation and IgH g-1 Class switching in response to gene gun vaccines. J. Immunol. 186, 1377-1383 (2011)
115. Hickling J, Jones R. Intradermal Delivery of Vaccines: a Review of the Literature and the Potential for Development for Use in Low- and Middle-Income Countries. PATH and WHO. 1-94 (2009)
116. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr. Top. Microbiol. Immunol. 333, 369-393 (2009)
117. Coulman SA, Birchall JC, Alex A et al. In vivo, in situ imaging of microneedle insertion into the skin of human volunteers using optical coherence tomography. Pharm. Res. 28, 66-81 (2011)
118. Wilke N, Mulcahy A, Ye S-R, Morrissey A. Process optimization and characterization of silicon microneedles fabricated by wet etch technology. Microelectronics J. 36, 650-656 (2005) (Pubitemid 40973306)
119. Moore AC, Carey JB, Crean A, Vrdoljak A, McGrath M, O'Mahony C. Percutaneous immunization using ImmuPatch: needle-free vaccination that results in stronger T cell and antibody responses compared with traditional immunization routes. Presented at: Vaccine and ISV Annual Conference, Vienna, Austria 07.4 (2010)
120. Chen X, Fernando GJP, Crichton ML et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J. Control. Rel. DOI: 10.1016/j.jconrel.2011.02. 026 (2011) (Epub ahead of print)
121. Badran MM, Kuntsche J, Fahr A. Skin penetration enhancement by a microneedle device (Dermaroller®) in vitro: dependency on needle size and applied formulation. Eur. J. Pharm. Sci. 36, 511-523 (2009)
122. Sullivan SP, Koutsonanos DG, del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nature Med. Suppl. 16(8), 915-921 (2010)
123. IntercellAG. Intercell Platform Technologies and Products. Company report. 1-62 (2009)
124. Rosati M, Valentin A, Jalah R et al. Pavlakis: increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26, 5223-5229 (2008)
125. Tjelle TE, Salte R, Mathiesen I, Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 24, 4667-4670 (2006) (Pubitemid 43776760)
126. Kitzmueller S, Weiss R, Hessenberger M, Boehler C, Thalhamer J, Scheiblhofer S. Transdermal vaccine delivery via laser-generated micropores. Vaccine and ISV Annual Conference, Vienna. P2.1.09 (2010)
127. Kalia YN, Bachhav YG, Bragagna T, Böhler C. P.L.E.A.S.E.® (Painless Laser Epidermal System): a new laser microporation technology. Drug Deliv. Technol. 8(5), 26-31 (2008)
128. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Exp. Opin. Drug Deliv. 3(1), 87-95 (2006) (Pubitemid 43056393)
129. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685-696 (2007)
130. Henao-Restrepo AM, Greco M, Laurie X, John O, Aguado T. Project tWPDGfMA: measles aerosol vaccine project. Procedia in Vaccinology 2, 147-150 (2010)
131. De Filette M, Fiers W, Martens W et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24(44-46), 6597-6601 (2006) (Pubitemid 46127431)
132. Lambkin R, Oxford JS, Bossuyt S et al. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine 4390-4396 (2004) (Pubitemid 39330364)
133. Slütter B, Bal SM, Que I et al. Antigen- adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharmac. 7(6), 2207-2215 (2010)
134. Sievers RE, Cape SP, Kisich KO et al. Challenges of developing a stable dry powder live viral vaccine. In: RDD 2008. Dalby RN (Ed.)Scottsdale, Arizona, USA (2008).
135. Cape SP, McAdams DH, Manion JaR et al. Inhalable dry powder live-attenuated measles virus vaccine prepared by the CAN-BD process, a novel spray drying alternative to lyophilisation. CHI PepTalk. San Diego, CA, USA (2010)
136. Amorij J-P, Saluja V, Petersen AH, Hinrichs WLJ, Huckriede A, Frijlink HW. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice. Vaccine 8707-8717 (2007) (Pubitemid 350199597)
137. McAdams DH, Cape SP, Frederick ED, Garcea RL, Sievers RE. Characterization of myo-inostitol as a particle-forming and stabilizing excipient for inhalable measles and human papillomavirus vaccines. In: RDD 2010. Dalby RN (Ed.)Orlando, FL, USA (2010)
138. Sievers RE, Cape SP, McAdams DH et al. Inhalation delivery of aerosols of unit-dose dry powder vaccines vs. liquid vaccines. ISAM Conference. Monterey, CA, USA (2009)
139. Kisich KO, Higgins MP, Park I et al. Dry powder measles vaccine: particle deposition, virus replication, and immune response in cotton rats following inhalation. Vaccine 29(5), 905-912 (2011)
140. Lin W-H, Griffin DE, Rota PA et al. Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques. PNAS 108(7), 2987-2992 (2011)
141. Sievers RE, Best JA, Cape SP. Human-powered dry powder inhaler and dry powder inhaler compositions. International Patent Application (WO 2008/021451 A2), 1-33 (2008)
142. Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Exp. Opin. Drug Deliv. DOI: 10.1517/17425247.2010.53837 (2010) (Epub ahead of print)
143. Kaye RS, Purewal TS, Alpar OH. Development and testing of particulate formulations for the nasal delivery of antibodies. J. Control. Release 135, 127-135 (2009)
144. Scherließ R, Trows S. Novel formulation concept for particulate uptake of vaccines via the nasal associated lymphoid tissue. Procedia in Vaccinology. Manuscript accepted (2011)
145. Lebre F, Borchard G, de Lima MCP, Borges O. Progress towards a needle-free hepatitis B vaccine. Pharm. Res. 28, 986-1012 (2011)
146. WHO. Recommended Routine Immunization-Summary of WHO Position Papers (2010)
147. Loudon PT, Yager EJ, Lynch DT et al. GM-CSF Increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS ONE 5(6), e11021 (2010)
148. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 337(1-2), 1-24 (2007) (Pubitemid 46756063)
149. Marx D, Leitz M, Pfitzer K. Intranasal vaccination. Inhalation 4(3), 8-11 (2010)
150. Chiarello K. Bi-directional nasal device delivers drug on exhalation. Pharmac. Science Technol. News 15-18 (2004)
151. de Swart RL, Kuiken T, Fernandez-de Castro J et al. Aerosol measles vaccination in macaques: preclinical studies of immune responses and safety. Vaccine 24, 6424-6436 (2006). (Pubitemid 44331997)